Your browser doesn't support javascript.
loading
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Vasseur, Antoine; Cabel, Luc; Tredan, Olivier; Chevrier, Marion; Dubot, Coraline; Lorgis, Véronique; Jacot, William; Goncalves, Anthony; Debled, Marc; Levy, Christelle; Ferrero, Jean-Marc; Jouannaud, Christelle; Luporsi, Elisabeth; Mouret-Reynier, Marie-Ange; Dalenc, Florence; Lemonnier, Jerome; Savignoni, Alexia; Tanguy, Marie-Laure; Bidard, Francois-Clement; Pierga, Jean-Yves.
Affiliation
  • Vasseur A; Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris & Saint Cloud, France.
  • Cabel L; Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris & Saint Cloud, France.
  • Tredan O; UVSQ, Paris-Saclay University, Saint Cloud, France.
  • Chevrier M; Department of Medical Oncology, Leon Berard Center, Lyon, France.
  • Dubot C; Department of Biostatistics, Institut Curie, PSL Research University, Paris & Saint Cloud, France.
  • Lorgis V; Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris & Saint Cloud, France.
  • Jacot W; Department of Medical Oncology, Georges-François Leclerc Center, Dijon, France.
  • Goncalves A; Department of Medical Oncology, Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, IRCM INSERM U1194, Montpellier, France.
  • Debled M; Aix-Marseille Univ, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Levy C; Department of Medical Oncology, Institut Bergonie, Bordeaux, France.
  • Ferrero JM; Department of Medical Oncology, François Baclesse Center, Caen, France.
  • Jouannaud C; Department of Medical Oncology, Antoine Lacassagne Center, Nice, France.
  • Luporsi E; Department of Medical Oncology, Institut Jean Godinot, Reims, France.
  • Mouret-Reynier MA; Department of Medical Oncology, ICL Alexis Vautrin, Vandoeuvre Les Nancy, France.
  • Dalenc F; Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France.
  • Lemonnier J; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
  • Savignoni A; R&D UNICANCER, UCBG, Paris, France.
  • Tanguy ML; Department of Biostatistics, Institut Curie, PSL Research University, Paris & Saint Cloud, France.
  • Bidard FC; Department of Biostatistics, Institut Curie, PSL Research University, Paris & Saint Cloud, France.
  • Pierga JY; Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris & Saint Cloud, France.
Angiogenesis ; 23(2): 193-202, 2020 05.
Article in En | MEDLINE | ID: mdl-31773439
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Endothelial Cells / Bevacizumab / Neoplastic Cells, Circulating Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Angiogenesis Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Endothelial Cells / Bevacizumab / Neoplastic Cells, Circulating Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Angiogenesis Year: 2020 Document type: Article